BioM and Lonza virtual symposium

Digitally delivered | Wednesday 30 June 2021

Gain insight and discuss the challenges and solutions of early stage biopharmaceutical development

BioM and Lonza Biologics are pleased to invite you to join us for a complimentary virtual symposium to gain insight from experts in the different approaches and techniques to successfully progress biotherapeutic candidates from discovery to the clinic.The symposium includes presentations from industry experts, local biotech companies and technical specialists from Lonza.

Our networking breaks and virtual lunch offer the opportunity to speak with fellow scientists, presenters and Lonza subject matter experts. You will also have the opportunity to book a virtual consultancy session with one of Lonza’s scientists, which will take place after the symposium.

 

Register Here


Insight and discussion with our experts


Agenda (all times CET)

08.30 am – 08.45 am Welcome and overview of symposium
Dr. Horst Domsday | CEO BioM
Moderator: Dr. Hari Kumar | Pharmaceutical Executive; Independent Board Member; former CEO Adheron Therapeutics
08.45 am – 09.20 am Keynote presentation
Academic opinion leader | Institute - TBC
09.20 am – 9.45 am Right First Time: Optimize and De-risk Your Early Development Journey
Dr. Yvette Stallwood | Head of Applied Protein Services, Lonza
09:45 am – 10.10 am

Making the Right Match – 21st Century Antibody-Drug Conjugates 9ADCs) for Targeted Cancer Therapy
Dr. Jonas Helma-Smets  | CSO, Tubulis

10.10 am – 10.30 am Virtual Coffee Break | Networking Tables with Speakers
10:30 am – 11.00 am piggyBac’ing Bioprocessing: Improving Expression of Complex Proteins with a Toolbox Approach
Dr. Peter O’Callaghan | Principal Scientist, Lonza
11.00 – 11.25 am Single-cell Dispensing Technologies for the Development of Microbial Expression Strains
Dr. Julian Riba  | CSO, Cytena
11.25 am – 11.50 am
Microbial Strain Development – Using Combinatorial Screening Strategies to Make an Informed Decision on Host Selection for Preclinical to Commercial Manufacture
Dr. Joachim Klein | Head of Strain Development and Cell Banking, Microbial Development Services, Lonza
11.50 am – 12.30 pm
Virtual Networking Lunch | Networking Tables with Speakers
12.30 pm – 12.55 pm
Biological Diversity Enabling Therapeutic Precision
Dr. med. Daniel Parera | Co-CEO and CMO, IcanoMAB and Dr. Ulrich Pessara | CBO, IcanoMAB
12.55 pm – 13.20 pm

Engineering the Neutralizing Antibody COR-101 for the Treatment of Moderate to Severe COVID-19
Prof. Dr. Stefan Duebel | Professor Technische Universität Braunschweig/Co-Founder YuMab GmbH

13.20 pm – 13.45 pm Title - TBC
Dr. Martin Steegmaier | SVP Head of Research, MorphoSys
13.45 pm – 13.50 pm Wrap Up and End of Symposium

Register Here